Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual

2016 ◽  
Vol 41 (6) ◽  
pp. 727-729 ◽  
Author(s):  
S. W. Johnson ◽  
M. M. Davis ◽  
L. M. Stever ◽  
D. H. Priest
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Treatment Success ◽  
Chronic Hepatitis C Virus ◽  
Experienced Individual

New treatment options of chronic hepatitis C virus infection

2011 ◽  
Vol 152 (22) ◽  
pp. 887-897 ◽  
Author(s):  
Béla Hunyady
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Rapid Development ◽  
Treatment Options ◽  
Treatment Success ◽  
Hepatocellular Cancer ◽  
Hepatic Decompensation ◽  
Chronic Hepatitis C Virus

Chronic hepatitis C virus (HCV) infection is the major etiology and the reason of chronic liver disease, liver cirrhosis, hepatic decompensation, hepatocellular cancer and liver transplantation. Less than half of patients with HCV-related chronic hepatitis achieve sustained viral clearance with current pegylated interferon and ribavirin (P+R) combination therapy. Due to the insufficient treatment success, an extended search for new, direct acting anti-HCV agents (DAAs) is ongoing, already leading to submissions of applications for marketing authorization of the protease-inhibitors boceprevir and telaprevir. Both are effective only in triple combinations with P+R. Studies demonstrate a 50% success rate advantage for triple therapies above current standards. In addition, treatment duration can be shortened, and half of the patients who failed previous therapy with P+R can be cured with triple therapies. A major concern with new DAAs is rapid development of DAA-resistant viral mutants, a reason as well as a consequence of insufficient triple therapy. Clinical studies with boceprevir and telaprevir are reviewed in this paper. Orv. Hetil., 2011, 152, 887–897.

Sign in / Sign up

Export Citation Format

Share Document